Clinical-practice decisions regarding glycoprotein IIb/IIIa inhibitors in acute coronary syndromes should be based on overall trial results rather than inappropriate post-randomization subgroup analyses.
Clinical practice decisions and guidelines should be based on overall trial results rather than post-randomization subgroup analyses, which can be misleading.
BACKGROUND: Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used only in acute coronary syndrome patients undergoing percutaneous coronary intervention, supporting data from randomized clinical trials are tenuous. The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup analyses performed across the glycoprotein IIb/IIIa inhibitor trials. METHODS AND RESULTS: We describe the problems with these analytical techniques and demonstrate that different approaches to the question can result in opposing answers. CONCLUSIONS: Clinical-practice decisions and practice guidelines should be based on overall trial results and not analyses of post-randomization subgroups.
Pieper et al. (2004) conducted a review in Acute Coronary Syndromes. Platelet glycoprotein IIb/IIIa inhibitors was evaluated. Clinical-practice decisions regarding glycoprotein IIb/IIIa inhibitors in acute coronary syndromes should be based on overall trial results rather than inappropriate post-randomization subgroup analyses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: